Literature DB >> 1647181

The molecular pharmacology of doxorubicin in vivo.

J Cummings1, L Anderson, N Willmott, J F Smyth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1647181     DOI： 10.1016/0277-5379(91)90209-v

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  27 in total

1.  Protein phosphatase 5 and the tumor suppressor p53 down-regulate each other's activities in mice.

Authors:  Jun Wang; Tao Shen; Wuqiang Zhu; Longyu Dou; Hao Gu; Lingling Zhang; Zhenyun Yang; Hanying Chen; Qi Zhou; Edwin R Sánchez; Loren J Field; Lindsey D Mayo; Zhongwen Xie; Deyong Xiao; Xia Lin; Weinian Shou; Weidong Yong
Journal:  J Biol Chem       Date:  2018-09-27       Impact factor: 5.157

2.  Characterization of alkylating versus intercalating anticancer drug-induced effects on cell survival, cell cycle kinetic and morphonuclear pattern of three neoplastic cells lines growing in vitro.

Authors:  O Pauwels; R Kiss; J L Pasteels; G Atassi
Journal:  Pharm Res       Date:  1995-07       Impact factor: 4.200

3.  Formation of adriamycin--DNA adducts in vitro.

Authors:  C Cullinane; S M Cutts; A van Rosmalen; D R Phillips
Journal:  Nucleic Acids Res       Date:  1994-06-25       Impact factor: 16.971

4.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

5.  Inhibition of Epstein-Barr-virus-transformed human chronic lymphocytic leukaemic B cells with monoclonal-antibody-adriamycin (doxorubicin) conjugates.

Authors:  Z Zhu; J Kralovec; T Ghose; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1995-04       Impact factor: 6.968

6.  Proteomic analysis of the vitamin C effect on the doxorubicin cytotoxicity in the MCF-7 breast cancer cell line.

Authors:  Peter Bober; Michal Alexovic; Ivan Talian; Zuzana Tomkova; Zuzana Viscorova; Maria Benckova; Igor Andrasina; Rachele Ciccocioppo; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak; Jan Sabo
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

7.  Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats.

Authors:  Gregory W Konat; Michal Kraszpulski; Isaac James; Han-Ting Zhang; Jame Abraham
Journal:  Metab Brain Dis       Date:  2008-08-09       Impact factor: 3.584

8.  Superoxide induces protein oxidation in plasma and TNF-α elevation in macrophage culture: Insights into mechanisms of neurotoxicity following doxorubicin chemotherapy.

Authors:  Jeriel T R Keeney; Sumitra Miriyala; Teresa Noel; Jeffrey A Moscow; Daret K St Clair; D Allan Butterfield
Journal:  Cancer Lett       Date:  2015-07-28       Impact factor: 8.679

9.  Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain.

Authors:  G Joshi; C D Aluise; M P Cole; R Sultana; W M Pierce; M Vore; D K St Clair; D A Butterfield
Journal:  Neuroscience       Date:  2010-01-20       Impact factor: 3.590

10.  Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG).

Authors:  I Berger; L Su; J R Spitzner; C Kang; T G Burke; A Rich
Journal:  Nucleic Acids Res       Date:  1995-11-11       Impact factor: 16.971
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.